Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
David Stover, Encino, CA (US); Dhruba Bharali, Sherman Oaks, CA (US); Bruce A Hay, Niskayuna, NY (US); and Tahmineh Safaie, Los Angeles, CA (US)
Assigned to Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed by Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed on Dec. 21, 2020, as Appl. No. 16/974,306.
Claims priority of provisional application 62/974,746, filed on Dec. 20, 2019.
Prior Publication US 2021/0187066 A1, Jun. 24, 2021